Kedar S. Vaidya

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Darren C. Phillips, Michael J. Mitten, Erwin R. Boghaert et al. · Science Translational Medicine · 2015 · 530 citations · Full text

Cancer Therapy, Chemoprevention Strategy, Bcl-2/bcl-xl/bcl-w Inhibitor Abt-263 +20

Breast Cancer Metastasis Suppressor 1 Up-regulates miR-146, Which Suppresses Breast Cancer Metastasis

Douglas R. Hurst, Mick D. Edmonds, Gary K. Scott et al. · Cancer Research · 2009 · 424 citations · Full text

ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

Andrew C. Phillips, Erwin R. Boghaert, Kedar S. Vaidya et al. · Molecular Cancer Therapeutics · 2016 · 175 citations · Full text

Tumor Biology, Drug Targeting, Tumor-selective Egfr Epitope +15

Requirement of KISS1 Secretion for Multiple Organ Metastasis Suppression and Maintenance of Tumor Dormancy

K. Nash, Pushkar Phadke, Jean Marc Navenot et al. · JNCI Journal of the National Cancer Institute · 2007 · 164 citations · Full text

ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both <i>MET</i> –Amplified and c-Met–Overexpressing Tumors, Irrespective of <i>MET</i> Pathway Dependence

Jieyi Wang, Mark G. Anderson, Anatol Oleksijew et al. · Clinical Cancer Research · 2016 · 127 citations · Full text